MX2024003770A - Compuestos de imidazopiridazina inhibidores de il-17. - Google Patents
Compuestos de imidazopiridazina inhibidores de il-17.Info
- Publication number
- MX2024003770A MX2024003770A MX2024003770A MX2024003770A MX2024003770A MX 2024003770 A MX2024003770 A MX 2024003770A MX 2024003770 A MX2024003770 A MX 2024003770A MX 2024003770 A MX2024003770 A MX 2024003770A MX 2024003770 A MX2024003770 A MX 2024003770A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- imidazopyridazine
- inhibitor compounds
- compounds
- ameliorating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248563P | 2021-09-27 | 2021-09-27 | |
| US202163273407P | 2021-10-29 | 2021-10-29 | |
| US202263371910P | 2022-08-19 | 2022-08-19 | |
| PCT/US2022/077000 WO2023049886A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003770A true MX2024003770A (es) | 2024-06-19 |
Family
ID=83693127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003770A MX2024003770A (es) | 2021-09-27 | 2022-09-26 | Compuestos de imidazopiridazina inhibidores de il-17. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12215111B2 (https=) |
| EP (1) | EP4408529A1 (https=) |
| JP (1) | JP2024536863A (https=) |
| KR (1) | KR20240082371A (https=) |
| AU (1) | AU2022348938A1 (https=) |
| CA (1) | CA3233625A1 (https=) |
| MX (1) | MX2024003770A (https=) |
| TW (1) | TW202329933A (https=) |
| UY (1) | UY39957A (https=) |
| WO (1) | WO2023049886A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240082371A (ko) | 2021-09-27 | 2024-06-10 | 얀센 파마슈티카 엔브이 | 이미다조피리다진 il-17 억제제 화합물 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| WO2024138286A1 (en) * | 2022-12-26 | 2024-07-04 | Usynova Pharmaceuticals, Ltd. | Il-17a modulators |
| WO2024163365A1 (en) * | 2023-01-30 | 2024-08-08 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| WO2025202922A1 (en) * | 2024-03-27 | 2025-10-02 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| KR20230019507A (ko) | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| KR20240082371A (ko) | 2021-09-27 | 2024-06-10 | 얀센 파마슈티카 엔브이 | 이미다조피리다진 il-17 억제제 화합물 |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
| TW202413363A (zh) | 2021-11-04 | 2024-04-01 | 大陸商西藏海思科製藥有限公司 | 一種可抑制il-17a之雜環化合物及其用途 |
-
2022
- 2022-09-26 KR KR1020247013538A patent/KR20240082371A/ko active Pending
- 2022-09-26 AU AU2022348938A patent/AU2022348938A1/en active Pending
- 2022-09-26 UY UY0001039957A patent/UY39957A/es not_active Application Discontinuation
- 2022-09-26 WO PCT/US2022/077000 patent/WO2023049886A1/en not_active Ceased
- 2022-09-26 CA CA3233625A patent/CA3233625A1/en active Pending
- 2022-09-26 JP JP2024518817A patent/JP2024536863A/ja active Pending
- 2022-09-26 TW TW111136298A patent/TW202329933A/zh unknown
- 2022-09-26 EP EP22790173.3A patent/EP4408529A1/en active Pending
- 2022-09-26 MX MX2024003770A patent/MX2024003770A/es unknown
- 2022-09-26 US US17/935,329 patent/US12215111B2/en active Active
-
2024
- 2024-12-09 US US18/973,307 patent/US20250206744A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12215111B2 (en) | 2025-02-04 |
| CA3233625A1 (en) | 2023-03-30 |
| US20230147458A1 (en) | 2023-05-11 |
| UY39957A (es) | 2023-04-14 |
| EP4408529A1 (en) | 2024-08-07 |
| WO2023049886A1 (en) | 2023-03-30 |
| AU2022348938A1 (en) | 2024-05-16 |
| TW202329933A (zh) | 2023-08-01 |
| US20250206744A1 (en) | 2025-06-26 |
| JP2024536863A (ja) | 2024-10-08 |
| KR20240082371A (ko) | 2024-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| MX2024003772A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MX2024003770A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| GEP20257750B (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| WO2024026433A3 (en) | Novel dpp1 inhibitors and uses thereof | |
| MX2023013080A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| MX2026001061A (es) | Inhibidores de la fosfatidilinositol 3-cinasa (pi3k) | |
| CR20200620A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer campo | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| MX2021012706A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| CY1109763T1 (el) | Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης | |
| CR20240043A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| MX2022013401A (es) | Compuestos de azalactama como inhibidores de hpk1. | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| MX2024008868A (es) | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |